Oxazepam
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
Oxazepam: Predicted New Indication for insomnia (disease)
One-Sentence Summary
Oxazepam is a short-acting benzodiazepine originally used for alcohol withdrawal delirium and anxiety. The TxGNN model predicts it may be effective for insomnia, with no registered clinical trials but 10 publications (including 2 randomized trials) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alcohol withdrawal delirium; anxiety |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 9 of 9) |
| Number of DINs | 9 (marketed: 9) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known class pharmacology, oxazepam is a benzodiazepine that enhances inhibitory GABA-A receptor signalling. This produces calming and sedative-hypnotic effects.
Anxiety and insomnia often occur together, and the same GABA-A mechanism that reduces anxiety also promotes sleep. This makes the prediction pharmacologically plausible, and the very high TxGNN score is consistent with it.
There are important limits. Benzodiazepines used as hypnotics carry risks of tolerance, dependence, withdrawal, next-day impairment, and problems in older adults. The supporting evidence is mostly small, older studies and reviews, not registered trials.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6691478 | 1984 | RCT | Am J Psychiatry | In 14 patients with chronic insomnia, oxazepam and flurazepam improved some polysomnographic sleep measures; flurazepam caused marked daytime sleepiness, oxazepam did not |
| 29749262 | 2018 | RCT | Ann Pharmacother | Melatonin vs oxazepam for anxiety and sleep quality in STEMI patients after primary PCI |
| 17317444 | 2007 | Observational study (60 patients) | Arch Gerontol Geriatr | Effectiveness and safety of hypnotics for insomnia in people over 70 |
| 23330992 | 2013 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics of anxiolytic drugs |
| 36340306 | 2022 | Review | J Clin Exp Hepatol | Management of alcohol withdrawal syndrome in alcoholic liver disease; insomnia is a common symptom |
| 29844949 | 2018 | Cohort | PeerJ | Potentially inappropriate long-term benzodiazepine and z-drug use in older people |
| 6139491 | 1983 | Cohort | JAMA | Withdrawal syndrome after switching from a long-acting to a short-acting benzodiazepine, including oxazepam |
| 15633073 | 2005 | Review | Psychiatr Prax | Management of behavioural and psychological symptoms of dementia |
Two further retrieved papers (agomelatine case report, paroxetine in panic disorder) have little direct relevance to oxazepam and are not listed.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00402737 | APO-OXAZEPAM | Not specified | Not specified |
| 00497754 | PRO-OXAZEPAM | Not specified | Not specified |
| 00497762 | PRO-OXAZEPAM | Not specified | Not specified |
| 00402745 | APO-OXAZEPAM | Not specified | Not specified |
| 00402680 | APO-OXAZEPAM | Not specified | Not specified |
Nine valid single-ingredient licences are held in total (APO-, PRO- and RIVA-OXAZEPAM); five are shown here.
Safety Considerations
- Contraindications (model-derived associations, not label text): Associated conditions include porphyria, kidney disease, liver disease, gallbladder disease, psychotic disorders, sleep apnea syndromes, respiratory failure, lung disease, hypotensive disorder, substance-related disorders and personality disorders. These associations come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
- Drug Interactions: 100 interactions were found. Major interactions include morphine (including liposomal morphine), which raises the risk of additive central nervous system and respiratory depression. Moderate interactions include bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine and teduglutide. Several antacids (magnesium oxide, calcium carbonate, aluminum hydroxide and others) show minor interactions.
- Class-related concerns (from the literature): tolerance, dependence, withdrawal on dose changes or switching, and inappropriate long-term use in older adults.
Please refer to the package insert for official warnings, as label text was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and the TxGNN score is high, but the support is limited to a few small, older studies and reviews, with no registered trials. Official label warnings are not yet reviewed. Benzodiazepine hypnotic use also has well-known risks, particularly in older adults.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, and approved indication text for each DIN
- Mechanism of action data from DrugBank
- Comparison with current first-line insomnia treatments, including non-drug options
- A risk-benefit assessment covering dependence and withdrawal, older adults, and opioid co-use
- Recent controlled trials of oxazepam specifically in insomnia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.